Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Hikma Pharmaceuticals    HIK   GB00B0LCW083

News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Hikma Pharmaceuticals : Announces Expanded Licensing Agreement with Takeda for New Products in the Middle East and North Africa

share with twitter share with LinkedIn share with facebook
share via e-mail
08/21/2017 | 09:06am CEST

DUBAI, UAE: PRNewswire: Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, through its wholly-owned subsidiary Hikma Pharmaceuticals LLC has reached an agreement with Takeda Pharmaceutical Company Limited (Takeda) to expand its licensing and distribution agreement with the global research and development-driven pharmaceutical company, adding new products to its portfolio in the Middle East and North Africa (MENA). Hikma will have the right to register, manufacture, market, distribute and sell four of Takeda’s leading primary care products in 17 markets in the MENA region.

Under the terms of the agreement, which is effective immediately for all markets, Hikma has the exclusive rights to manufacture and commercialise three of Takeda’s leading primary care product families – Alogliptin, including Alogliptin/Metformin, Alogliptin/Pioglitazone (anti-diabetic), Azilsartan, including Azilsartan/Chlorothalidone (anti-hypertensive) and Lornoxicam in its rapid form (anti-inflammatory/ pain) – in its MENA markets. The agreement, however, does not include the Egyptian market for Alogloptin. Hikma also has exclusive rights to manufacture and commercialise Takeda’s Dexlansoprozole in its MENA markets, with the exception of Saudi Arabia, the UAE and Egypt. Hikma’s existing license agreement with Takeda in respect of Lornoxicam tablets (anti-inflammatory/ pain), has been expanded beyond Saudi Arabia and Jordan to cover Hikma’s other MENA markets.

The new agreement builds on a long-standing strategic partnership between Hikma and Takeda. It leverages Hikma’s substantial sales and manufacturing presence in the MENA and extensive experience of building brands in the region.

Mazen Darwazah, Executive Vice Chairman and CEO of MENA and Emerging Markets said, “Our large sales and marketing teams, with particular expertise in promoting cardiovascular and diabetes treatments, are well positioned to drive strong demand for Takeda’s products. We are pleased to be building on our partnership with Takeda to bring important medicines to the MENA region. By working with global partners we are strengthening our product portfolio in growing therapeutic areas and reinforcing our commitment to improving patient access to quality medicines.”

In turn, Danilo Cassani, Takeda’s Vice President and Area Head Near East, Middle East & Africa said, “At Takeda, we put patients at the centre of everything we do. As such, our partnership with Hikma is a testament of our commitment to offer patients world-class cardiovascular and metabolism (CVM) medicines while keeping focus on our core therapeutic areas of oncology and gastroenterology. This will help better serve the unmet medical needs of patients.”

About Hikma Pharmaceuticals:

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma’s operations are conducted through three businesses: “Branded”, “Injectables” and “Generics”, based primarily in the Middle East and North Africa (“MENA”) region, where it is a market leader, the United States and Europe. Hikma currently employs over 8,500 staff members worldwide.

About Takeda:

Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries.

(c) 2017 mid-east.info Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
09:06a HIKMA PHARMACEUTICALS : Announces Expanded Licensing Agreement with Takeda for N..
08/19 HIKMA PHARMACEUTICALS : and Takeda sign new licensing agreement to expand produc..
08/18 VECTURA : Hikma Interim Results statement on its ANDA for generic Advair Diskus
08/18 HIKMA PHARMACEUTICALS : delivers stable profitability and strong cash generation..
08/18 HIKMA PHARMACEUTICALS : Shares in Hikma slide as generics woes drag on
08/17 Fed-fuelled banking stumble cuts short FTSE winning streak
08/17 Drugmaker Hikma trims sales forecasts, shares fall
08/17 HIKMA PHARMACEUTICALS : Takeda, Hikma in new licensing pact for Mena
08/17 HIKMA PHARMACEUTICALS : announces new licensing agreement with Takeda for produc..
08/16 HIKMA PHARMACEUTICALS PLC : - Notice of results
More news
News from SeekingAlpha
08/18 Hikma Pharmaceuticals' (HKMPF) CEO Said Darwazah on Q2 2017 Results - Earning..
08/17 Hikma Pharmaceuticals plc. 2017 Q2 - Results - Earnings Call Slides
08/17 Hikma Pharmaceuticals reports 1H results
06/08 Jazz Keeps The Narcolepsy Market Awake
05/12 'MAJOR' REPRIEVE NUMBER TWO : Another Stumble For GlaxoSmithKline's Advair Block..
Financials ($)
Sales 2017 2 045 M
EBIT 2017 376 M
Net income 2017 219 M
Debt 2017 471 M
Yield 2017 2,08%
P/E ratio 2017 15,82
P/E ratio 2018 11,56
EV / Sales 2017 1,92x
EV / Sales 2018 1,71x
Capitalization 3 464 M
Duration : Period :
Hikma Pharmaceuticals Technical Analysis Chart | HIK | GB00B0LCW083 | 4-Traders
Technical analysis trends HIKMA PHARMACEUTICALS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 13
Average target price 23,2 $
Spread / Average Target 61%
EPS Revisions
Said Samih Taleb Darwazah Chairman & Chief Executive Officer
Khalid Nabilsi Chief Financial Officer
Ibrahim Jalal Senior Vice President-Technical Affairs
Mazen Samih Taleb Darwazah Executive Vice Chairman & CEO-MENA Region
Mohammed Ali Khaldoun Al-Husry Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.12%355 979
NOVARTIS7.69%216 915
ROCHE HOLDING LTD.3.78%216 699
PFIZER0.59%194 554